Aspirin is the Antiplatelet Drug of Choice for Acute Ischemic Cerebral Infarct
For acute ischemic stroke, initiate aspirin 160-300 mg within 48 hours of symptom onset 1. This represents the standard of care based on the 2018 AHA/ASA guidelines and is supported by large-scale clinical trials demonstrating prevention of approximately 10 deaths and early recurrent strokes per 1,000 patients treated 2.
Administration Details
- Dosing: 160-300 mg (not the previously recommended 325 mg, as trials supporting efficacy used this lower range) 1
- Timing: Within 48 hours of stroke onset 2
- Route: Oral if patient can swallow safely; otherwise rectal suppository or nasogastric administration 1, 2
Critical Exceptions and Special Circumstances
When NOT to Use Aspirin
- Do not substitute aspirin for IV alteplase or mechanical thrombectomy in eligible patients (Class III recommendation) 1
- Delay antiplatelet therapy if thrombolysis is administered; timing should be individualized balancing hemorrhage risk versus benefit 1
Minor Stroke Exception (NIHSS <6)
For minor stroke presenting within 24 hours, dual antiplatelet therapy (aspirin + clopidogrel) for 21 days is superior to aspirin alone (Class IIa recommendation) 1. This provides better early secondary stroke prevention for up to 90 days from symptom onset.
- Ticagrelor is NOT recommended over aspirin for minor stroke (Class III: No Benefit) 1
- Despite guideline support, aspirin-ticagrelor remains infrequently used in practice (only 1.3% of eligible patients) 3
Alternative Antiplatelet Agents
If aspirin is contraindicated, alternative antiplatelet agents may be reasonable 1. However:
- Clopidogrel alone: Acceptable alternative 4, 5
- Glycoprotein IIb/IIIa inhibitors (abciximab): Potentially harmful and should NOT be used (Class III: Harm) 1
- IV tirofiban and eptifibatide: Efficacy not well established; further trials needed 1
Common Pitfalls to Avoid
- Do not delay aspirin beyond 48 hours - the benefit is time-dependent 2
- Do not use aspirin doses >300 mg - no additional benefit and worse gastrointestinal tolerance 5
- Do not withhold aspirin in atrial fibrillation patients during acute phase - aspirin is safe and effective even in cardioembolic stroke acutely, though long-term anticoagulation will be needed 5, 6
- Do not continue dual antiplatelet therapy beyond 21-90 days in minor stroke - increased bleeding risk without sustained benefit 1
Evidence Strength
The aspirin recommendation is based on Class I, Level B-R evidence from the AHA/ASA guidelines 1, supported by large randomized trials (IST and CAST) involving thousands of patients 2. The dual antiplatelet recommendation for minor stroke reflects more recent evidence with Class IIa, Level B-R designation 1.